Abstract
In this issue of JEM, Zhang et al. (https://doi.org/10.1084/jem.20250339) report that a gain-of-function mutation in CARMIL2, previously identified in patients, is sufficient to replace the contribution of CD28 to NF-κB activation and downstream effects in T cells, including in the setting of an anti-tumor response.